Am J Blood Res 2011;1(1):46-56
Review Article
The ubiquitin-proteasomal system is critical for multiple myeloma:
implications in drug discovery
Biyin Cao, Xinliang Mao
Cyrus Tang Hematology Center, Jiangsu Institute of Hematology, The First Affiliated Hospital, Soochow University, Suzhou,
China.
Received May 9, 2011; accepted May 23, 2011; Epub May 25, 2011; published June 15, 2011
Abstract: Bortezomib is a specific inhibitor of proteasomes, the most important protease complexes in protein degradation.
Bortezomib can induce apoptosis of a variety of cancer cells, including leukemia, lymphoma, multiple myeloma, breast
cancers, prostate cancers, lung cancers, and so on. However, extensive studies and overall evaluation suggested that
multiple myeloma is the most sensitive and the best responsive disease which was later approved by Food and Drug
Administration for bortezomib treatment. Because proteasomes are an essential component in the ubiquitin-proteasomal
protein degradation pathway, the discovery of bortezomib implicated that the UPS is critical for myeloma pathophysiology. The
UPS also contains ubiquitin, ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2), ubiquitin ligase (E3) and
deubiquitinase (Dubs). In this review, we examined and analyzed the recent advancements of the UPS components in
multiple myeloma and its implications in drug discovery for myeloma treatment. (AJBR1105002).
Keywords: Ubiquitin-proteasomal system, bortezomib, myeloma, drug discovery
Full Text PDF
Address all correspondence to:
Xinliang Mao, PhD
Cyrus Tang Hematology Center
Soochow University
199 Ren Ai Road, Suzhou Industrial Park
Suzhou, Jiangsu Province, 215123
P.R.China
Tel/Fax: +86-512-65882123
E-mail: Xinliangmao@suda.edu.cn
Review Article
The ubiquitin-proteasomal system is critical for multiple myeloma:
implications in drug discovery
Biyin Cao, Xinliang Mao
Cyrus Tang Hematology Center, Jiangsu Institute of Hematology, The First Affiliated Hospital, Soochow University, Suzhou,
China.
Received May 9, 2011; accepted May 23, 2011; Epub May 25, 2011; published June 15, 2011
Abstract: Bortezomib is a specific inhibitor of proteasomes, the most important protease complexes in protein degradation.
Bortezomib can induce apoptosis of a variety of cancer cells, including leukemia, lymphoma, multiple myeloma, breast
cancers, prostate cancers, lung cancers, and so on. However, extensive studies and overall evaluation suggested that
multiple myeloma is the most sensitive and the best responsive disease which was later approved by Food and Drug
Administration for bortezomib treatment. Because proteasomes are an essential component in the ubiquitin-proteasomal
protein degradation pathway, the discovery of bortezomib implicated that the UPS is critical for myeloma pathophysiology. The
UPS also contains ubiquitin, ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2), ubiquitin ligase (E3) and
deubiquitinase (Dubs). In this review, we examined and analyzed the recent advancements of the UPS components in
multiple myeloma and its implications in drug discovery for myeloma treatment. (AJBR1105002).
Keywords: Ubiquitin-proteasomal system, bortezomib, myeloma, drug discovery
Full Text PDF
Address all correspondence to:
Xinliang Mao, PhD
Cyrus Tang Hematology Center
Soochow University
199 Ren Ai Road, Suzhou Industrial Park
Suzhou, Jiangsu Province, 215123
P.R.China
Tel/Fax: +86-512-65882123
E-mail: Xinliangmao@suda.edu.cn
| AJBR Copyright © 2011-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711, USA |
 |  |  |  |  |  |  |